We are live on
!
Find out more
DM
Deerfield Management Portfolio holdings
AUM
$8.48B
1-Year Est. Return
99.04%
This Fund
S&P 500
This Quarter
Est. Return
-0.62%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$5.63B
AUM Growth
+$871M
(+18%)
Cap. Flow
-$403M
Cap. Flow
% of AUM
-7.15%
Top 10 Holdings %
Top 10 Hldgs %
32.98%
Holding
166
New
29
Increased
30
Reduced
12
Closed
23
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
OMIC
Singular Genomics Systems, Inc. Common Stock
OMIC
|
+$235M |
| 2 |
AdaptHealth
AHCO
|
+$145M |
| 3 |
CMAX
CareMax, Inc. Class A Common Stock
CMAX
|
+$132M |
| 4 |
Organogenesis Holdings
ORGO
|
+$78.8M |
| 5 |
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
|
+$50.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Boston Scientific
BSX
|
+$110M |
| 2 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$88.6M |
| 3 |
Biogen
BIIB
|
+$86.7M |
| 4 |
Centene
CNC
|
+$67.9M |
| 5 |
The Oncology Institute
TOI
|
+$55M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 68.23% |
| 2 | Consumer Discretionary | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Viatris
VTRS
$20.1B
| $269M | 4.78% |
18,824,000
+1,600,000
| +9% | +$23.1M |
|
|
OMIC
2
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
| $250M | 4.45% |
+303,734
| New | +$235M |
|
|
CMAX
3
DELISTED
CareMax, Inc. Class A Common Stock
CMAX
| $216M | 3.84% |
559,292
+333,334
| +148% | +$132M |
|
|
4
AdaptHealth
AHCO
$1.49B
| $202M | 3.58% |
7,353,792
+5,075,921
| +223% | +$145M |
|
|
5
Organogenesis Holdings
ORGO
$337M
| $120M | 2.13% |
7,222,127
+4,226,489
| +141% | +$78.8M |
|
6
Edgewise Therapeutics
EWTX
$4.28B
| $83.9M | 1.49% |
3,933,137
| – | – |
|
7
Pulmonx
LUNG
$59.1M
| $79.5M | 1.41% |
1,800,887
+863,855
| +92% | +$37.6M |
|
|
AFIB
8
DELISTED
Acutus Medical Inc
AFIB
| $73.7M | 1.31% |
4,341,799
| – | – |
|
|
9
Centene
CNC
$32.8B
| $72.6M | 1.29% |
995,000
-990,619
| -50% | -$67.9M |
|
10
Neurocrine Biosciences
NBIX
$17.2B
| $70.6M | 1.25% |
725,000
| – | – |
|
11
Pacira BioSciences
PCRX
$1.01B
| $69.6M | 1.24% |
1,147,000
-17,973
| -2% | -$1.14M |
|
12
Protagonist Therapeutics
PTGX
$9.06B
| $61.2M | 1.09% |
1,362,790
+104,000
| +8% | +$3.43M |
|
13
Mirum Pharmaceuticals
MIRM
$7.25B
| $59.6M | 1.06% |
3,448,912
| – | – |
|
14
Molina Healthcare
MOH
$11.7B
| $58.7M | 1.04% |
231,776
| – | – |
|
15
Larimar Therapeutics
LRMR
$384M
| $57.3M | 1.02% |
5,830,249
+685,710
| +13% | +$7.75M |
|
|
SILK
16
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
| $54.5M | 0.97% |
1,138,525
+649,980
| +133% | +$33.1M |
|
17
Zimmer Biomet
ZBH
$17.6B
| $54.4M | 0.97% |
348,140
-19,570
| -5% | -$3.17M |
|
|
CNST
18
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
| $54.1M | 0.96% |
1,601,427
-107,530
| -6% | -$2.74M |
|
19
QuidelOrtho
QDEL
$1.19B
| $52.4M | 0.93% |
+409,219
| New | +$48.2M |
|
20
Alphatec Holdings
ATEC
$1.31B
| $52.1M | 0.93% |
3,402,384
+200,468
| +6% | +$3.09M |
|
|
KALV
21
DELISTED
KalVista Pharmaceuticals
KALV
| $51.8M | 0.92% |
2,163,554
+1,143,549
| +112% | +$29.9M |
|
|
22
The Oncology Institute
TOI
$535M
| $49.8M | 0.88% |
5,000,000
-5,460,000
| -52% | -$55M |
|
23
Revolution Medicines
RVMD
$39.6B
| $49.7M | 0.88% |
1,565,712
+129,000
| +9% | +$4.5M |
|
|
DCPH
24
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $49.2M | 0.87% |
1,343,560
+814,975
| +154% | +$31.6M |
|
|
SWTX
25
DELISTED
SpringWorks Therapeutics
SWTX
| $46M | 0.82% |
558,574
| – | – |
|
Similar funds
FT
GRQ
AV
PCM
VA
QC
IC
NW
Deerfield Management's Q2 2021 Portfolio in Review
As of Q2 2021, Deerfield Management held 166 positions worth $5.63B, up 18% from $4.76B the previous quarter. Its ten largest holdings account for 33% of the portfolio.
Deerfield Management withdrew a net $403M in Q2 2021, closing 23 positions and reducing 12 holdings. Its most notable exit was Boston Scientific, an estimated $110M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 68% of assets, down from 71% a quarter earlier, followed by Consumer Discretionary.
Against the trend, Deerfield Management opened a new position in Singular Genomics Systems, Inc. Common Stock worth $250M.
- Deerfield Management's largest Q2 2021 buy was Singular Genomics Systems, Inc. Common Stock: 303,734 shares worth $250M.
- Deerfield Management added most to AdaptHealth in Q2 2021, an estimated $145M increase.
- Deerfield Management's biggest Q2 2021 reduction was Centene, cutting an estimated $67.9M.
- Deerfield Management fully exited Boston Scientific in Q2 2021, selling an estimated $110M.
- Deerfield Management's ten largest holdings make up 33% of its $5.63B portfolio in Q2 2021.
- Deerfield Management opened 29 new positions and closed 23 in Q2 2021.
- Deerfield Management's portfolio value rose 18% quarter-over-quarter to $5.63B.
Based on Deerfield Management's 13F filing for Q2 2021, filed 16 Aug 2021.